- Home
- RARE vs ESTA Comparison
RARE vs ESTA Comparison
Compare RARE & ESTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | ESTA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Costa Rica |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RARE | ESTA |
|---|---|---|
| Price | $23.86 | $66.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 7 |
| Target Price | $73.11 | ★ $78.86 |
| AVG Volume (30 Days) | ★ 2.7M | 487.0K |
| Earning Date | 02-13-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | $190,973,000.00 |
| Revenue This Year | $20.17 | $29.16 |
| Revenue Next Year | $19.10 | $25.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 20.63 | ★ 24.76 |
| 52 Week Low | $18.41 | $26.56 |
| 52 Week High | $46.50 | $78.24 |
Technical Indicators
Market Signals| Indicator | RARE | ESTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 46.18 |
| Support Level | $23.26 | $63.00 |
| Resistance Level | $25.82 | $73.99 |
| Average True Range (ATR) | 1.02 | 3.61 |
| MACD | 0.43 | 0.27 |
| Stochastic Oscillator | 48.69 | 31.71 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.